Dai Fukumura
Harvard University
312 Papers
2.3K Citations
Dai Fukumura is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Angiogenesis. The author has an hindex of 100, co-authored 292 publications. Previous affiliations of Dai Fukumura include Massachusetts Institute of Technology & Keio University.
Chat about Author
Papers
Photodynamic therapy for cancer
TL;DR: PDT is being tested in the clinic for use in oncology — to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin.
5.4K
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
Peter Carmeliet,Yuval Dor,Jean-Marc Herbert,Dai Fukumura,Koen Brusselmans,Mieke Dewerchin,Michal Neeman,Françoise Bono,Rinat Abramovitch,Patrick H. Maxwell,Cameron J. Koch,Peter J. Ratcliffe,Lieve Moons,Rakesh K. Jain,Desire Collen,Eli Keshert +15 more
TL;DR: It is shown that hypoxia and hypoglycaemia reduce proliferation and increase apoptosis in wild-type (Hif-1α+/+) embryonic stem (ES) cells, but not in ES cells with inactivated HIF-1 α genes (HIF- 1α−/−), suggesting that there are at least two different adaptive responses to being deprived of oxygen and nutrients.
2.5K
•Journal Article
Vascular Permeability in a Human Tumor Xenograft: Molecular Size Dependence and Cutoff Size
Fan Yuan,Marc Dellian,Dai Fukumura,Michael Leunig,David A. Berk,Vladimir P. Torchilin,Rakesh K. Jain +6 more
TL;DR: Tumor vessels in the model found that tumor vessels in this model were permeable to liposomes of up to 400 nm in diameter, suggesting that the cutoff size of the pores is between 400 and 600nm in diameter.
1.8K
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
TL;DR: The roles of VEGF and ANG2 are outlined, and ways that antiangiogenic agents can be combined with immune-checkpoint inhibitors to potentially improve patient outcomes are suggested, and avenues of future research are highlighted.
Normalization of the vasculature for treatment of cancer and other diseases
TL;DR: The pathophysiology of tumor angiogenesis, the molecular underpinnings and functional consequences of vascular normalization, and the implications for treatment of cancer and nonmalignant diseases are reviewed.